

# VACCINATE WOMEN

A periodical for obstetrician/gynecologists from the Immunization Action Coalition

Highlighting the latest developments in routine immunization and hepatitis B prevention.

## Ask the Experts

*Editor's note: The Immunization Action Coalition thanks William L. Atkinson, MD, MPH, Andrew T. Kroger, MD, MPH, and Eric E. Mast, MD, MPH, of the Centers for Disease Control and Prevention (CDC) for answering the following questions for our readers. Dr. Atkinson is a medical epidemiologist, and Dr. Kroger is a medical officer, both at CDC's National Immunization Program. Dr. Mast is chief, Prevention Branch, at CDC's Division of Viral Hepatitis.*

### Immunization Questions

by William L. Atkinson, MD, MPH  
and Andrew T. Kroger, MD, MPH

#### How common is human papillomavirus (HPV) infection?

HPV is the most common sexually transmitted infection in the United States. Currently, more than 20 million men and women in the United States are infected with HPV, and more than 6 million are estimated to become infected each year. HPV is most common in young women and men in their late teens and early 20s. By age 50, at least 80 percent of sexually active women will have acquired HPV infection.

#### How serious is disease caused by HPV?

HPV infection can lead to cervical cancer in women as well as to other cancers that can affect males or females. Cervical cancer is diagnosed in more than 9,700 women each year in the United States each year and causes 3,700 deaths. Seventy percent of cervical cancers are caused by strains of HPV included in the newly licensed HPV vaccine. HPV also causes genital warts in men and women.

#### Please provide more information about the new HPV vaccine.

Gardasil™, manufactured by Merck, is the first vaccine developed to prevent cervical cancer, precancerous genital lesions, and genital warts due to HPV. The vaccine is highly effective against four types of the HPV virus, including two that cause about 70 percent of cervical cancer. HPV-vaccine recipients who have not acquired HPV would get the full benefits of the vaccine. Though women already infected with an HPV vaccine type virus will not benefit from that part of the vaccine, they could still benefit from the other vaccine virus types.

#### What are the recommendations for use of HPV vaccine?

The Advisory Committee on Immunization Practices (ACIP) voted to recommend that it be routinely given to girls ages 11–12 years, though it can be given to girls as young as 9 years. ACIP also voted to recommend that girls and women ages 13 through 26 years receive the vaccine. Ideally vaccine should be administered before onset of

sexual activity, but sexually active females should still be vaccinated.

Gardasil is licensed as a 3-dose series, with dose #2 given 2 mos after dose #1, and dose #3 given 4 mos after dose #2. The vaccine should be given IM in the deltoid. ACIP recommendations do not become official until they are published in the *MMWR*, which is expected to occur later this year. ACOG will be publishing recommendations for the use of HPV vaccine soon. For more information on the use of HPV vaccine, consult the package insert: [www.fda.gov/cber/label/hpvmer060806LB.pdf](http://www.fda.gov/cber/label/hpvmer060806LB.pdf).

#### If a woman is diagnosed with HPV, should she still be vaccinated?

Yes. Although the vaccine would not alter the clinical course of the current infection, she would still benefit from protection against the other virus types in the vaccine.

#### Since men transmit HPV, why isn't the vaccine recommended for them also?

Studies of the safety and immunogenicity among males are not yet complete. It is possible that HPV vaccine will be recommended for males at a later date.

### Immunization questions?

- Call the CDC-INFO Contact Center at (800) 232-4636 or (800) CDC-INFO
- Email [nipinfo@cdc.gov](mailto:nipinfo@cdc.gov)
- Call your state health dept. (phone numbers at [www.immunize.org/coordinators](http://www.immunize.org/coordinators))

#### What is the Current Procedural Terminology (CPT) code for HPV vaccine?

It is 90649. CPT codes are used for billing.

#### Which adults should receive Tdap (the pertussis-containing vaccine for adults)?

A one-time dose of Tdap should replace a dose of Td for any adult younger than age 65 years, either as part of a primary series of tetanus and diphtheria toxoid or as a 10-year booster. Certain adults should get Tdap with an interval of 2 years or less following their previous Td dose if they are (1) a

(continued on page 2)

I'm really glad to have a vaccine that will protect me against cervical cancer!

Yes, it's great news to hear that CDC's advisory committee voted to recommend that all girls and women ages 11 through 26 receive three doses.



*Elaine Hester-Hamm*

### What's Inside?

Ask the Experts .....	1
Guidelines to Prevent Perinatal HBV Infection .....	4
Recommendations for Adult Immunization .....	5
How to Administer IM and SC Injections .....	8
Screening Questionnaire for Adult Immunization .....	9
Do I Need Any Vaccinations Today? .....	10
Essential Immunization Resources from IAC .....	11
Vaccines Safeguard Women's Health .....	12

## Vaccinate Women

### Immunization Action Coalition

#### Hepatitis B Coalition

1573 Selby Avenue, Suite 234  
St. Paul, MN 55104  
Phone: (651) 647-9009  
Fax: (651) 647-9131  
Email: admin@immunize.org  
Websites: www.immunize.org  
www.vaccineinformation.org  
www.hepprograms.org  
www.izcoalitions.org

*Vaccinate Women* is a publication of the Immunization Action Coalition (IAC) written especially for obstetrician/gynecologists. All information contained in *Vaccinate Women* is reviewed by the Centers for Disease Control and Prevention (CDC) for technical accuracy. Circulation is 45,000. ISSN 1538-1978

This publication is supported by Grant No. U50/CCU523259 from CDC. The American College of Obstetricians and Gynecologists (ACOG) has generously provided us with distribution services. The contents are solely the responsibility of IAC and do not necessarily represent the official views of CDC or ACOG.

#### Publication Staff

Editor: Deborah L. Wexler, MD  
Associate Editor: Diane C. Peterson  
Managing Editor: Dale Thompson  
Editorial Asst.: Janelle Tangonan Anderson  
Consultant: Linda A. Moyer, RN  
Layout: Kathy Cohen

#### IAC Staff

Assistant to the Director: Becky Payne  
Office Administrator: Robin VanOss  
Administrative Asst.: Susan Broadribb  
Website Design: Lantern Web™

*IAC Express* is IAC's free email news and announcement service. To subscribe, send an email to [express@immunize.org](mailto:express@immunize.org) with the word SUBSCRIBE in the "Subject" field.

IAC, a 501(c)3 nonprofit organization, publishes practical immunization information for health professionals to help increase immunization rates and prevent disease.

The Hepatitis B Coalition, a program of IAC, promotes hepatitis B vaccination for all persons ages 0–30 years; HBsAg screening for all pregnant women; testing and vaccination for high-risk groups; and education and treatment for people chronically infected with hepatitis B virus.

### Board of Directors

**Diane Holmgren**  
St. Paul Ramsey County Public Health  
**Anne Kuettel, PHN**  
St. Paul Ramsey County Public Health  
**James McCord, MD**  
Children's Hospitals & Clinics  
**Cindy Uldrich**  
United HealthCare  
**Deborah L. Wexler, MD**  
Immunization Action Coalition

parent or caregiver of a child younger than age 12 months, (2) a healthcare worker having direct patient contact, or (3) at risk for pertussis due to increased pertussis activity or during outbreaks.

#### Which Tdap products can be used in adults?

Adacel (sanofi pasteur) is licensed for use in persons ages 11–64 years. Boostrix® (GlaxoSmithKline) is licensed for use in persons ages 10–18 years. Neither product is licensed for persons ages 65 years and older, so Td should be used in this age group whenever needed.

#### Can Tdap be given to pregnant women?

ACIP recently voted to recommend using Td (not Tdap) during pregnancy if a routine tetanus booster is needed. If the previous Td booster was given within the preceding 10 years, the new mother should receive Tdap immediately postpartum. However there are situations when a clinician can consider the use of Tdap for a pregnant woman, such as if there is a risk of exposure because of a pertussis outbreak. Tdap is not contraindicated for pregnant women. The infant's other household contacts ages 10–64 years should also receive Tdap.

#### I heard there is a new vaccine to prevent shingles. How effective is it and how should it be used?

In May 2006, the FDA licensed Zostavax® by Merck to prevent herpes zoster (shingles) as a 1-dose vaccination for all persons ages 60 years and older. In clinical trials, Zostavax reduced the risk of developing shingles by 51 percent, compared with placebo. ACIP has not yet made recommendations for the use of Zostavax.

#### Which healthcare workers in Ob/Gyn practices need influenza vaccine?

All of them. It is important to vaccinate all outpatient and hospital healthcare personnel who have contact with patients.

#### Which of my patients should be vaccinated against influenza?

Influenza vaccination is recommended for all women who will be pregnant during the influenza season (December through March) during any trimester. Additionally, influenza vaccine should be administered to (1) all persons age 50 years or older, (2) all persons with chronic medical conditions (e.g., pulmonary/cardiovascular, diabetes), (3) all persons who live with a person who has a high-risk condition and/or all persons who are caretakers or household contacts of children ages birth to 5 years. Influenza vaccine can also be given to any person who wishes to be protected against influenza.

#### How can I stay up to date on all that's new in immunization?

One easy method is to sign up for *IAC Express*, a

weekly (and sometimes more often) email news service from IAC. Simply go to [www.immunize.org/express](http://www.immunize.org/express) and subscribe. It's available free of charge.

#### Where can I find information on vaccine handling and storage?

A toolkit containing general guidelines for correct vaccine storage and handling can be found on CDC's website at [www2a.cdc.gov/nip/isd/shtoolkit/splash.html](http://www2a.cdc.gov/nip/isd/shtoolkit/splash.html).

#### How can our nursing staff stay current on immunization techniques?

A video "Immunization Techniques: Safe, Effective, Caring," is available in VHS tape and DVD disk formats. It can be ordered at [www.immunize.org/iztech](http://www.immunize.org/iztech).

#### Where can I get samples of standing orders for various vaccines?

IAC has developed standing orders for most childhood and adult vaccines. You can find them at [www.immunize.org/standingorders](http://www.immunize.org/standingorders).

## Hepatitis B

by Eric E. Mast, MD, MPH

#### Where can I obtain a copy of the new ACIP hepatitis B recommendations for infants, children, and teens?

These recommendations were published in *MMWR* on 12/23/05. The entire document is available at [www.cdc.gov/mmwr/pdf/rr/rr5416.pdf](http://www.cdc.gov/mmwr/pdf/rr/rr5416.pdf). In addition, CDC released a "Dear Colleague" letter that summarizes succinctly the updated hepatitis B recommendations that prenatal care providers, delivery hospitals, newborn care providers, and health departments should follow to prevent perinatal and early childhood HBV transmission. To obtain the letter, go to [www.immunize.org/acip/HBVinfant\\_dearcolleague.pdf](http://www.immunize.org/acip/HBVinfant_dearcolleague.pdf).

#### How have the universal hepatitis B birth dose recommendations been strengthened?

The recommendations to administer hepatitis B vaccine at birth now include the following:

- All delivery hospitals should implement standing orders for administration of hepatitis B vaccine as part of routine medical care of all medically stable infants weighing 2 kg (4.4 lb) or more at birth.
- All medically stable infants weighing 2 kg or more at birth and born to HBsAg-negative mothers should receive the first dose of vaccine before hospital discharge.
- On a case-by-case basis and only in rare circumstances, the first dose may be delayed until after hospital discharge for an infant who weighs 2 kg or more and whose mother is HBsAg negative. When such a decision is made, a physician's order

DISCLAIMER: *Vaccinate Women* is available to all readers free of charge. Some of the information in this issue is supplied to us by the Centers for Disease Control and Prevention in Atlanta, Georgia, and some information is supplied by third-party sources. The Immunization Action Coalition (IAC) has used its best efforts to accurately publish all of this information, but IAC cannot guarantee that the original information as supplied by others is correct or complete, or that it has been accurately published. Some of the information in this issue is created or compiled by IAC. All of the information in this issue is of a time-critical nature, and we cannot guarantee that some of the information is not now outdated, inaccurate, or incomplete. IAC cannot guarantee that reliance on the information in this issue will cause no injury. Before you rely on the information in this issue, you should first independently verify its current accuracy and completeness. IAC is not licensed to practice medicine or pharmacology, and the providing of the information in this issue does not constitute such practice. Any claim against IAC must be submitted to binding arbitration under the auspices of the American Arbitration Association in Saint Paul, Minnesota.

not to give the birth dose must be written, and a copy of the original laboratory report indicating that the mother was HBsAg negative during this pregnancy should be placed in the infant's medical record.

**Do AAP, AAFP, and ACOG all agree with the birth dose recommendations from CDC?**

Yes.

**What are the new recommendations for prenatal HBsAg testing and management of pregnant women?**

- All pregnant women should be tested routinely for HBsAg during an early prenatal visit (e.g., first trimester) in **each** pregnancy, even if they have been previously vaccinated or tested.
- Women who were not screened prenatally, those with clinical hepatitis, and those who engage in behaviors that put them at increased risk for HBV infection (e.g., recent or current injection drug use, having had sex with more than one partner in the previous 6 months or with an HBsAg-positive partner, or evaluation or treatment for an STD) should be tested at the time of admission to the hospital for delivery.
- All laboratories that provide HBsAg testing of pregnant women should use an FDA-licensed or FDA-approved HBsAg test and should perform testing according to the manufacturer's labeling. This includes testing of initially reactive specimens with a licensed neutralizing confirmatory test.
- When pregnant women are tested for HBsAg at the time of admission for delivery, shortened testing protocols may be used and initially reactive results should be reported to expedite administration of immunoprophylaxis to infants.
- Women who are HBsAg positive should be referred to an appropriate case-management program to ensure that their infants receive timely postexposure prophylaxis and follow-up.
- A copy of the original lab report indicating the pregnant woman's HBsAg status should be provided to the hospital where delivery is planned

and to the healthcare provider who will care for the newborn.

- Women who are HBsAg positive should be provided with or referred for appropriate counseling and medical evaluation and receive information concerning hepatitis B that discusses
  - modes of transmission;
  - perinatal concerns (e.g., infants who are born to HBsAg-positive mothers may be breast-fed);
  - prevention of HBV transmission to contacts, including the importance of postexposure immunoprophylaxis for the newborn infant and hepatitis B vaccination for household, sexual, and needle-sharing contacts;
  - substance abuse treatment, if appropriate;
  - medical evaluation and possible treatment of chronic hepatitis B.
- When HBsAg testing of pregnant women is not feasible (i.e., in remote areas without access to a laboratory), all infants should receive hepatitis B vaccine no later than 12 hours after birth and should complete the hepatitis B vaccine series according to a recommended schedule for infants born to HBsAg-positive mothers.

**Are all HBsAg-positive test results for pregnant women supposed to be reported to the state health department?**

Yes. This reporting is critical as it helps assure appropriate case management of infants born to HBV-infected mothers and counseling and medical evaluation for the infected mothers.

**Advisory Board**

**Liaisons from Organizations**

- William L. Atkinson, MD, MPH**  
*National Immunization Program, CDC*
- Stephen L. Cochi, MD, MPH**  
*National Immunization Program, CDC*
- Lawrence J. D'Angelo, MD, MPH**  
*Society for Adolescent Medicine*
- Stanley A. Gall, MD**  
*Amer. College of Obstetricians & Gynecologists*
- Bruce Gellin, MD, MPH**  
*National Vaccine Program Office, DHHS*
- Neal A. Halsey, MD**  
*Institute for Vaccine Safety, Johns Hopkins Univ.*
- Samuel L. Katz, MD**  
*Pediatric Infectious Diseases Society*
- Mary Beth Koslap-Petraco, RN-CS, CPNP**  
*National Assn. of Pediatric Nurse Practitioners*
- Marie-Michele Leger, MPH, PA-C**  
*American Academy of Physician Assistants*
- Harold S. Margolis, MD**  
*Pediatric Dengue Vaccine Initiative*
- Martin G. Myers, MD**  
*National Network for Immunization Information*
- Kathleen M. Neuzil, MD, MPH**  
*American College of Physicians*
- Paul A. Offit, MD**  
*Vaccine Education Ctr., Children's Hosp. of Phila.*
- Walter A. Orenstein, MD**  
*Emory Vaccine Center, Emory University*
- Mitchel C. Rothholz, RPh**  
*American Pharmacists Association*
- Thomas N. Saari, MD**  
*American Academy of Pediatrics*
- William Schaffner, MD**  
*Infectious Diseases Society of America*
- Anne Schuchat, MD**  
*National Immunization Program, CDC*
- Thomas E. Stenvig, RN, PhD**  
*American Nurses Association*
- Litjen Tan, PhD**  
*American Medical Association*
- John W. Ward, MD**  
*Division of Viral Hepatitis, NCID, CDC*
- Patricia N. Whitley-Williams, MD**  
*National Medical Association*
- Walter W. Williams, MD, MPH**  
*Office of Minority Health, CDC*

**Individuals**

- Anthony Chen, MD**  
*International Community Health Svcs., Seattle*
- Hie-Won L. Hann, MD**  
*Jefferson Medical College, Philadelphia, PA*
- Neal Holtan, MD, MPH**  
*St. Paul Ramsey Co. Public Health, St. Paul, MN*
- Margaret K. Hostetter, MD**  
*Yale University, New Haven, CT*
- Mark A. Kane, MD, MPH**  
*Consultant, Seattle, WA*
- Edgar K. Marcuse, MD, MPH**  
*University of Washington School of Medicine*
- Brian J. McMahon, MD**  
*Alaska Native Medical Center, Anchorage, AK*
- Gregory A. Poland, MD**  
*Mayo Clinic, Rochester, MN*
- Sarah Jane Schwarzenberg, MD**  
*University of Minnesota*
- Coleman I. Smith, MD**  
*Minnesota Gastroenterology, Minneapolis, MN*
- Richard K. Zimmerman, MD, MPH**  
*University of Pittsburgh*

**Deborah L. Wexler, MD**  
*Executive Director*

**Visit IAC websites**

- [www.immunize.org](http://www.immunize.org)
- [www.vaccineinformation.org](http://www.vaccineinformation.org)
- [www.hepprograms.org](http://www.hepprograms.org)
- [www.izcoalitions.org](http://www.izcoalitions.org)

**Do you have patients who are HBsAg-positive?**

They need medical monitoring, including liver cancer screening; many can benefit from treatment.

The FDA licenses five medications for treatment in the United States. They are interferon alfa-2b and peginterferon alfa-2a (administered subcutaneously); and adefovir dipivoxil, entecavir, and lamivudine (administered orally).

Consult a liver specialist experienced in the treatment of viral hepatitis for appropriate monitoring guidelines and for help in determining which of your patients might benefit from treatment.

# Guidelines for Standing Orders in Labor & Delivery and Nursery Units to Prevent Hepatitis B Virus Transmission to Newborns

In December 2005, the Centers for Disease Control and Prevention (CDC) published updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for prevention of hepatitis B virus (HBV) infections in infants, children, and adolescents. The American Academy of Pediatrics, American Academy of Family Physicians, and American College of Obstetricians and Gynecologists have endorsed these recommendations. To obtain a copy of these recommendations, go to [www.cdc.gov/mmwr/PDF/rr/rr5416.pdf](http://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf).

CDC recommends that all delivery hospitals institute standing orders to ensure

- Administration of hepatitis B vaccine to all medically stable newborns weighing at least 2 kg (4.4 lb) at birth before discharge from the nursery.
- Identification of infants born to hepatitis B surface antigen (HBsAg)-positive mothers and infants born to mothers with unknown HBsAg status and administration of appropriate immunoprophylaxis to these infants.

The guidance below has been developed to help your hospital establish standing orders in the labor and delivery and nursery units and has been reviewed by CDC staff for consistency with ACIP recommendations.

## Labor and Delivery (L&D) standing orders

Upon admission, review the HBsAg<sup>1</sup> status of all pregnant women. You must review a copy of the mother's original laboratory report to verify that the correct test was performed during this pregnancy and to verify the test date. Do not rely on a transcribed test result!

### For women with a documented HBsAg test result

- Place a copy of the original laboratory report of the mother's HBsAg<sup>1</sup> test result into (1) the mother's L&D record and (2) the infant's medical record.
- If the mother is HBsAg positive, alert the nursery staff.
- If the mother is HBsAg negative and is at risk for HBV infection during this pregnancy (e.g., had more than one sex partner in the previous 6 months; had an HBsAg-positive sex partner; had evaluation or treatment for a sexually transmitted disease; currently uses or recently used injection drugs), perform a repeat test for HBsAg.<sup>1</sup> Instruct the laboratory to call L&D and the nursery with the HBsAg test result ASAP.

### For women without a documented HBsAg test result

- Perform HBsAg<sup>1</sup> testing ASAP on women who do not have a documented HBsAg test result from the current pregnancy.
- Instruct the lab to call L&D and the nursery with the HBsAg test result ASAP.

## Nursery standing orders

### For all newborns

- Review a copy of the mother's original HBsAg<sup>1</sup> lab report. Provide appropriate management based on (1) the mother's HBsAg status and (2) the infant's birth weight. Manage those who weigh less than 2 kg differently from those who weigh 2 kg or more (see below and footnotes 2, 5, 6).
- Ensure that a copy of the original maternal HBsAg<sup>1</sup> laboratory report is in the infant's medical record.

### For infants born to HBsAg-negative mothers

- Administer single-antigen hepatitis B vaccine (0.5 mL, IM) before discharge to all infants weighing at least 2 kg at birth.<sup>2,3,4</sup> Document the hepatitis B vaccine dose appropriately in the infant's medical record, including date and time of administration.
- Give the mother an immunization record card that includes the hepatitis B vaccination date, and explain the need for a complete hepatitis B vaccine series to fully protect her baby. Remind the mother to bring the card with her each time her baby sees a provider.

### For infants born to mothers with unknown HBsAg status

- Administer single-antigen hepatitis B vaccine (0.5 mL, IM) within 12 hours of birth.<sup>3,5</sup> Do not wait for test results to return before giving this dose of vaccine! Document the hepatitis B vaccine dose appropriately.
- Give the mother an immunization record card that includes the hepatitis B vaccination date. Explain the need for further doses to fully protect her baby. Remind

the mother to bring the card with her each time her baby sees a provider.

- Confirm that the laboratory has received serum for the mother's HBsAg<sup>1</sup> test. Verify when the HBsAg result will be available and that it will be reported to L&D and the nursery ASAP. If the nursery does not receive the report at the expected time, call the laboratory for the result.
- If the mother's HBsAg<sup>1</sup> test result comes back positive
  - Administer hepatitis B immune globulin (HBIG 0.5 mL, IM) to the infant ASAP. Document the HBIG dose appropriately in the infant's medical record. There is little benefit in giving HBIG if more than 7 days have elapsed since birth.
  - Alert the mother's and infant's physician(s) of the test result.
  - Follow the instructions below for infants born to HBsAg-positive mothers.
- If the infant must be discharged before the HBsAg result is known
  - Document contact information for the parents (e.g., addresses, telephone numbers, emergency contacts) in case further treatment is needed.
  - Obtain the name, address, and phone number of the mother's and the infant's healthcare provider.
  - Notify the mother's and the infant's healthcare provider that the mother's HBsAg test result is pending.

### For infants born to HBsAg-positive mothers

- Administer HBIG (0.5 mL, IM) and single-antigen hepatitis B vaccine<sup>3,6</sup> (0.5 mL, IM) at separate injection sites within 12 hours of birth. Document the hepatitis B vaccine and HBIG doses appropriately in the infant's medical record, including date and time of administration.
- Give the mother an immunization record card that includes the date of the hepatitis B vaccine and HBIG doses, and explain the need for further doses of hepatitis B vaccine to fully protect her baby. Remind the mother to bring the card with her each time her baby sees a provider.
- Notify the local or state health department of the infant's birth and the date and time of administration of HBIG and hepatitis B vaccine doses.
- Obtain the name, address, and phone number of the infant's primary care provider. Notify the provider of the infant's birth, the date and time of HBIG and hepatitis B vaccine doses administered, and the importance of additional on-time vaccination and postvaccination testing of the infant for HBsAg and antibody to HBsAg after completion of the hepatitis B vaccine series.
- Provide advice to the mother. Tell her
  - About the importance of her infant completing the full hepatitis B vaccine series on schedule
  - About modes of HBV transmission and the need for vaccination of her susceptible household, sexual, and needle-sharing contacts
  - That she may breast-feed her infant upon delivery, even before hepatitis B vaccine and HBIG are given
  - That blood will need to be drawn from the infant after completion of the hepatitis B vaccine series at age 9–18 months to determine if the infant needs further management
  - That she needs to have a medical evaluation for chronic hepatitis B, including an assessment of whether she is eligible for antiviral treatment

### Footnotes

1. Be sure the correct test for HBsAg (hepatitis B surface antigen) was/is ordered. The HBsAg test should not be confused with other hepatitis B serologic tests, including antibody to HBsAg (anti-HBs or HBsAb) and antibody to hepatitis B core antigen (anti-HBc or HBcAb).
2. Infants weighing less than 2 kg whose mothers are documented to be HBsAg negative should receive the first dose of vaccine 1 month after birth or at hospital discharge. The mother's HBsAg status must be part of the infant's medical record.
3. Federal law requires that you give parents a Hepatitis B Vaccine Information Statement (VIS) before vaccine administration. To obtain a VIS, download from the IAC website at [www.immunize.org/vis](http://www.immunize.org/vis) or call your state health department.
4. Exceptions to giving the birth dose of hepatitis B vaccine are allowed on a case-by-case basis and only in rare circumstances. If a birth dose is not administered, a copy of the mother's negative HBsAg test result from the current pregnancy must be placed in the infant's medical record and the attending physician must write a specific order directing staff not to administer the birth dose in the hospital.
5. An infant weighing less than 2 kg whose mother's HBsAg status is unknown should receive HBIG and hepatitis B vaccine within 12 hours of birth. Do not count the hepatitis B vaccine dose as the first dose in the vaccine series. Reinitiate the full hepatitis B vaccine series at age 1–2 months.
6. An infant weighing less than 2 kg whose mother is HBsAg positive should receive the first dose of hepatitis B vaccine and HBIG within 12 hours of birth. Do not count the hepatitis B vaccine dose as the first dose in the vaccine series. Reinitiate the full hepatitis B vaccine series at age 1–2 months.

[www.immunize.org/catg.d/p2130per.pdf](http://www.immunize.org/catg.d/p2130per.pdf) • Item #2130 (4/06)

# Summary of Recommendations for Adult Immunization

Adapted from the recommendations of the Advisory Committee on Immunization Practices (ACIP)\* by the Immunization Action Coalition, July 2006

Vaccine name and route	For whom vaccination is recommended	Schedule for vaccine administration (any vaccine can be given with another)	Contraindications and precautions (mild illness is not a contraindication)
<p><b>Influenza</b> Trivalent inactivated influenza vaccine (TIV) <i>Give IM</i></p>	<ul style="list-style-type: none"> <li>• Persons age 50yrs and older.</li> <li>• Persons with medical problems (e.g., heart disease, lung disease, diabetes, renal dysfunction, hemoglobinopathy, immunosuppression) and/or people living in chronic-care facilities.</li> <li>• Persons with any condition that compromises respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration (e.g., cognitive dysfunction, spinal cord injury, seizure disorder, or other neuromuscular disorder).</li> <li>• Persons working or living with at-risk people.</li> <li>• Women who will be pregnant during the influenza season (December–March).</li> <li>• All healthcare workers and other persons who provide direct care to at-risk people.</li> <li>• Household contacts and out-of-home caregivers of children ages 0–59m.</li> <li>• Travelers at risk for complications of influenza who go to areas where influenza activity exists or who may be among people from areas of the world where there is current influenza activity (e.g., on organized tours).</li> <li>• Persons who provide essential community services.</li> <li>• Students or other persons in institutional settings (e.g., dormitory residents).</li> <li>• Anyone wishing to reduce the likelihood of becoming ill with influenza.</li> </ul>	<ul style="list-style-type: none"> <li>• Given every year in the fall or winter.</li> <li>• October and November are the ideal months to give TIV.</li> <li>• LAIV may be given as early as August.</li> <li>• Continue to give TIV and LAIV through the influenza season from December through March (including when influenza activity is present in the community) and at other times when the risk of influenza exists.</li> </ul>	<p><b>Contraindication</b> Previous anaphylactic reaction to this vaccine, to any of its components, or to eggs.</p> <p><b>Precaution</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• History of Guillain-Barré syndrome within 6wks of previous TIV.</li> </ul>
<p><b>Influenza</b> Live attenuated influenza vaccine (LAIV) <i>Give intranasally</i></p>	<ul style="list-style-type: none"> <li>• Healthy, non-pregnant persons age 49yrs and younger who meet any of the conditions listed below.               <ul style="list-style-type: none"> <li>- Working or living with at-risk people as listed in the section above.</li> <li>- Healthcare workers or other persons who provide direct care to at-risk people (except persons in close contact with severely immunosuppressed persons).</li> <li>- Household contacts and out-of-home caregivers of children ages 0–59m.</li> <li>- Travelers who may be among people from areas of the world where there is current influenza activity (e.g., on organized tours).</li> <li>- Persons who provide essential community services.</li> <li>- Students or other persons in institutional settings (e.g., dormitory residents).</li> <li>- Anyone wishing to reduce the likelihood of becoming ill with influenza.</li> </ul> </li> </ul>		<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylactic reaction to this vaccine, to any of its components, or to eggs.</li> <li>• Pregnancy, asthma, reactive airway disease or other chronic disorder of the pulmonary or cardiovascular system; an underlying medical condition, including metabolic disease such as diabetes, renal dysfunction, and hemoglobinopathy; a known or suspected immune deficiency disease or receiving immunosuppressive therapy; history of Guillain-Barré syndrome.</li> </ul> <p><b>Precaution</b> Moderate or severe acute illness.</p>
<p><b>Pneumococcal polysaccharide (PPV23)</b> <i>Give IM or SC</i></p>	<ul style="list-style-type: none"> <li>• Persons age 65yrs and older.</li> <li>• Persons who have chronic illness or other risk factors, including chronic cardiac or pulmonary disease, chronic liver disease, alcoholism, diabetes, CSF leak, as well as people living in special environments or social settings (including Alaska Natives and certain American Indian populations). Those at highest risk of fatal pneumococcal infection are persons with anatomic asplenia, functional asplenia, or sickle cell disease; immunocompromised persons including those with HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure, or nephrotic syndrome; persons receiving immunosuppressive chemotherapy (including corticosteroids); and those who received an organ or bone marrow transplant and candidates for or recipients of cochlear implants.</li> </ul>	<ul style="list-style-type: none"> <li>• Routinely given as a one-time dose; administer if previous vaccination history is unknown.</li> <li>• One-time revaccination is recommended 5yrs later for persons at highest risk of fatal pneumococcal infection or rapid antibody loss (e.g., renal disease) and for persons age 65yrs and older if the 1st dose was given prior to age 65 and 5yrs or more have elapsed since the previous dose.</li> </ul>	<p><b>Contraindication</b> Previous anaphylactic reaction to this vaccine or to any of its components.</p> <p><b>Precaution</b> Moderate or severe acute illness.</p>

\*For specific ACIP recommendations, refer to the official ACIP statements published in *MMWR*. To obtain copies of these statements, call the CDC-INFO Contact Center at (800) 232-4636; visit CDC’s website at [www.cdc.gov/nip/publications/ACIP-list.htm](http://www.cdc.gov/nip/publications/ACIP-list.htm); or visit the Immunization Action Coalition (IAC) website at [www.immunize.org/acip](http://www.immunize.org/acip).

This table is revised periodically. Visit IAC’s website at [www.immunize.org/adultrules](http://www.immunize.org/adultrules) to make sure you have the most current version. IAC thanks William Atkinson, MD, MPH, from CDC’s National Immunization Program for his assistance. For more information, contact IAC at 1573 Selby Avenue, St. Paul, MN 55104, (651) 647-9009, or email [admin@immunize.org](mailto:admin@immunize.org).

# Summary of Recommendations for Adult Immunization (continued)

Vaccine name and route	For whom vaccination is recommended	Schedule for vaccine administration (any vaccine can be given with another)	Contraindications and precautions (mild illness is not a contraindication)
<p><b>Hepatitis B</b> (Hep B) <i>Give IM</i></p> <p>Brands may be used interchangeably.</p>	<ul style="list-style-type: none"> <li>All adolescents; any adult wishing to obtain immunity.</li> <li>High-risk persons, including household contacts and sex partners of HBsAg-positive persons; injecting drug users; heterosexuals with more than one sex partner in 6 months; men who have sex with men; persons with recently diagnosed STDs; patients receiving hemodialysis and patients with renal disease that may result in dialysis; recipients of certain blood products; healthcare workers and public safety workers who are exposed to blood; clients and staff of institutions for the developmentally disabled; inmates of long-term correctional facilities; and certain international travelers.</li> <li>Persons with chronic liver disease.</li> </ul> <p><b>Note:</b> Provide serologic screening for immigrants from endemic areas. When HBsAg-positive persons are identified, offer appropriate disease management. In addition, screen their sex partners and household members, and give the first dose of vaccine at the same visit. If found susceptible, complete the vaccine series.</p>	<ul style="list-style-type: none"> <li>Three doses are needed on a 0, 1, 6m schedule.</li> <li>Alternative timing options for vaccination include 0, 2, 4m and 0, 1, 4m.</li> <li>There must be 4wks between doses #1 and #2, and 8wks between doses #2 and #3. Overall, there must be at least 16wks between doses #1 and #3.</li> <li><b>Schedule for those who have fallen behind:</b> If the series is delayed between doses, DO NOT start the series over. Continue from where you left off.</li> </ul> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> <p>For Twinrix™ (hepatitis A and B combination vaccine [GSK]), three doses are needed on a 0, 1, 6m schedule. Recipients must be age 18yrs or older.</p> </div>	<p><b>Contraindication</b> Previous anaphylactic reaction to this vaccine or to any of its components.</p> <p><b>Precaution</b> Moderate or severe acute illness.</p>
<p><b>Hepatitis A</b> (Hep A) <i>Give IM</i></p> <p>Brands may be used interchangeably.</p>	<ul style="list-style-type: none"> <li>Persons who travel or work anywhere except the U.S., Western Europe, New Zealand, Australia, Canada, and Japan.</li> <li>Persons with chronic liver disease, including persons with hepatitis B and C; injecting and non-injecting drug users; men who have sex with men; people with clotting-factor disorders; persons who work with hepatitis A virus in experimental lab settings (not routine medical laboratories); and food handlers when health authorities or private employers determine vaccination to be cost effective.</li> <li>Anyone wishing to obtain immunity to hepatitis A.</li> </ul> <p><b>Note:</b> Prevacination testing is likely to be cost effective for persons older than age 40yrs, as well as for younger persons in certain groups with a high prevalence of hepatitis A virus infection.</p>	<ul style="list-style-type: none"> <li>Two doses are needed.</li> <li>The minimum interval between doses #1 and #2 is 6m.</li> <li>If dose #2 is delayed, do not repeat dose #1. Just give dose #2.</li> </ul>	<p><b>Contraindication</b> Previous anaphylactic reaction to this vaccine or to any of its components.</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>Moderate or severe acute illness.</li> <li>Safety during pregnancy has not been determined, so benefits must be weighed against potential risk.</li> </ul>
<p><b>Td, Tdap</b> (Tetanus, diphtheria, pertussis) <i>Give IM</i></p>	<ul style="list-style-type: none"> <li>All adults who lack a history of a primary series consisting of at least 3 doses of tetanus- and diphtheria-containing vaccine.</li> <li>A booster dose of tetanus- and diphtheria-containing toxoid may be needed for wound management as early as 5yrs after receiving a previous dose, so consult ACIP recommendations.*</li> <li>Using tetanus toxoid (TT) instead of Td or Tdap is <u>not</u> recommended.</li> </ul> <p><u>For Tdap (tetanus- and diphtheria-toxoids with acellular pertussis vaccine) only:</u></p> <ul style="list-style-type: none"> <li>All adults younger than age 65yrs who have not received Tdap.</li> <li>Healthcare workers who work in hospitals or ambulatory care settings and have direct patient contact and who have not received Tdap.</li> <li>Adults in contact with infants younger than age 12m (e.g., parents, grandparents younger than age 65yrs, childcare providers, healthcare workers) who have not received a dose of Tdap.</li> </ul>	<ul style="list-style-type: none"> <li>For persons who are unvaccinated or behind, complete the primary series with Td (spaced at 0, 1–2m, 6–12m intervals). One dose of Tdap may be used for any dose if ages 19–64yrs.</li> <li>Give Td booster every 10yrs after the primary series has been completed. For adults ages 19–64yrs, a 1-time dose of Tdap is recommended to replace the next Td.</li> <li>Intervals of 2yrs or less between Td and Tdap may be used if needed.</li> </ul> <p><b>Note:</b> The 2 Tdap products are licensed for different age groups: Adacel (sanofi) for use in persons ages 11–64yrs and Boostrix (GSK) for use in persons ages 10–18yrs.</p>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>Previous anaphylactic reaction to this vaccine or to any of its components.</li> <li>For Tdap only, history of encephalopathy within 7 days following DTP/DTaP.</li> </ul> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>Moderate or severe acute illness.</li> <li>Guillain-Barré syndrome within 6wks of receiving a previous dose of tetanus toxoid-containing vaccine.</li> <li>Unstable neurologic condition.</li> <li>Pregnancy: if ≥10yrs since prior Td, give Td in 2nd or 3rd trimester; if &lt;10yrs, give Tdap in immediate postpartum period.</li> </ul>
<p><b>Polio</b> (IPV) <i>Give IM or SC</i></p>	<p>Not routinely recommended for persons age 18yrs and older.</p> <p><b>Note:</b> Adults living in the U.S. who never received or completed a primary series of polio vaccine need not be vaccinated unless they intend to travel to areas where exposure to wild-type virus is likely. Previously vaccinated adults can receive one booster dose if traveling to polio endemic areas.</p>	<ul style="list-style-type: none"> <li>Refer to ACIP recommendations* regarding unique situations, schedules, and dosing information.</li> </ul>	<p><b>Contraindication</b> Previous anaphylactic or neurologic reaction to this vaccine or to any of its components.</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>Moderate or severe acute illness.</li> <li>Pregnancy.</li> </ul>

# Summary of Recommendations for Adult Immunization (continued)

Vaccine name and route	For whom vaccination is recommended	Schedule for vaccine administration (any vaccine can be given with another)	Contraindications and precautions (mild illness is not a contraindication)
<p><b>Varicella</b> (Var) (Chickenpox) <i>Give SC</i></p>	<p>All susceptible adults and adolescents should be vaccinated. It is especially important to ensure varicella immunity among household contacts of immunosuppressed persons and among healthcare workers.</p>	<ul style="list-style-type: none"> <li>• Two doses are needed.</li> <li>• Dose #2 is given 4–8wks after dose #1.</li> <li>• If varicella vaccine and MMR are both needed and are not administered on the same day, space them at least 4wks apart.</li> <li>• If the second dose is delayed, do not repeat dose #1. Just give dose #2.</li> </ul>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylactic reaction to this vaccine or to any of its components.</li> <li>• Pregnancy or possibility of pregnancy within 4wks (use contraception).</li> <li>• Persons immunocompromised because of malignancies and primary or acquired cellular immunodeficiency including HIV/AIDS. (See <i>MMWR</i> 1999, Vol. 48, No. RR-6.) <b>Note:</b> For those on high-dose immunosuppressive therapy, consult ACIP recommendations regarding delay time.*</li> </ul> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• If blood, plasma, and/or immune globulin (IG or VZIG) were given in past 11m, see ACIP statement <i>General Recommendations on Immunization</i>* regarding time to wait before vaccinating.</li> <li>• Moderate or severe acute illness.</li> </ul>
<p><b>Meningococcal</b> Conjugate vaccine (MCV4) <i>Give IM</i> Polysaccharide vaccine (MPSV4) <i>Give SC</i></p>	<ul style="list-style-type: none"> <li>• College freshmen living in dormitories.</li> <li>• Adolescents and adults with anatomic or functional asplenia or with terminal complement component deficiencies.</li> <li>• Persons who travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of Sub-Saharan Africa).</li> <li>• Microbiologists who are routinely exposed to isolates of <i>N. meningitidis</i>.</li> </ul>	<ul style="list-style-type: none"> <li>• MCV4 is preferred over MPSV4 for persons age 55yrs and younger, although MPSV4 is an acceptable alternative.</li> <li>• Give one dose to persons with risk factors; revaccinate after 5yrs if risk of disease continues and previous vaccine was MPSV4.</li> </ul>	<p><b>Contraindication</b></p> <p>Previous anaphylactic or neurologic reaction to this vaccine or to any of its components, including diphtheria toxoid (for MCV4).</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• For MCV4 only, history of Guillain-Barré syndrome.</li> </ul>
<p><b>MMR</b> (Measles, mumps, rubella) <i>Give SC</i></p>	<ul style="list-style-type: none"> <li>• Persons born in 1957 or later (especially those born outside the U.S.) should receive at least one dose of MMR if there is no serologic proof of immunity or documentation of a dose given on or after the first birthday.</li> <li>• Persons in high-risk groups, such as healthcare workers, students entering college and other post–high school educational institutions, and international travelers, should receive a total of two doses.</li> <li>• Persons born before 1957 are usually considered immune, but proof of immunity (serology or vaccination) may be desirable for healthcare workers.</li> <li>• Women of childbearing age who do not have acceptable evidence of rubella immunity or vaccination.</li> </ul>	<ul style="list-style-type: none"> <li>• One or two doses are needed.</li> <li>• If dose #2 is recommended, give it no sooner than 4wks after dose #1.</li> <li>• If varicella vaccine and MMR are both needed and are not administered on the same day, space them at least 4wks apart.</li> <li>• If a pregnant woman is found to be rubella susceptible, administer MMR postpartum.</li> </ul>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylactic reaction to this vaccine or to any of its components.</li> <li>• Pregnancy or possibility of pregnancy within 4wks (use contraception).</li> <li>• Persons immunocompromised because of cancer, leukemia, lymphoma, immunosuppressive drug therapy, including high-dose steroids or radiation therapy. <b>Note:</b> HIV positivity is NOT a contraindication to MMR except for those who are severely immunocompromised.</li> </ul> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• If blood, plasma, and/or immune globulin were given in past 11m, see ACIP statement <i>General Recommendations on Immunization</i>* regarding time to wait before vaccinating.</li> <li>• Moderate or severe acute illness.</li> <li>• History of thrombocytopenia or thrombocytopenic purpura.</li> </ul> <p><b>Note:</b> If PPD (tuberculosis skin test) and MMR are both needed but not given on same day, delay PPD for 4–6wks after MMR.</p>
<p><b>Human-papillomavirus</b> (HPV) <i>Give IM</i></p>	<p>All previously unvaccinated women through age 26yrs.</p>	<ul style="list-style-type: none"> <li>• Three doses are needed.</li> <li>• Dose #2 is given 4–8wks after dose #1, and dose #3 is given 6mos after dose #1 (at least 10wks after dose #2).</li> </ul>	<p><b>Contraindication</b></p> <p>Previous anaphylactic reaction to this vaccine or to any of its components.</p> <p><b>Precaution</b></p> <p>Data on vaccination in pregnancy are limited; therefore, vaccination during pregnancy should be delayed until after completion of the pregnancy.</p>
<p><b>Zoster (shingles)</b> (Zos) <i>Give SC</i></p>	<p>A herpes zoster (shingles) vaccine was licensed in May 2006 for use in persons age 60yrs and older. ACIP recommendations for its use are pending. Refer to the package insert for details on its use.</p>		

# How to Administer IM and SC Injections to Adults

## Intramuscular (IM) Injections

### Administer these vaccines via IM route:

Tetanus, diphtheria (Td), or with pertussis (Tdap); hepatitis A; hepatitis B; human papillomavirus (HPV); trivalent inactivated influenza (TIV); and meningococcal conjugate (MCV4). Administer polio (IPV) and pneumococcal polysaccharide vaccine (PPV) either IM or SC.

### Injection site:


Give in the central and thickest portion of the deltoid—above the level of the armpit and below the acromion (see the diagram).

### Needle size:

22–25 gauge, 1–1½” needle

### Needle insertion:

- Use a needle long enough to reach deep into the muscle.
- Insert the needle at a 90° angle to the skin with a quick thrust.
- Separate two injections given in the same deltoid muscle by a minimum of 1”.



## Subcutaneous (SC) Injections

### Administer these vaccines via SC route:

MMR, varicella, meningococcal polysaccharide (MPSV4), and zoster (shingles). Administer polio (IPV) and pneumococcal polysaccharide vaccine (PPV) either SC or IM.

### Injection site:


Fatty tissue over the triceps (see the diagram)

### Needle size:

23–25 gauge, 5/8” needle

### Needle insertion:

- Pinch up on the tissue to prevent injection into the muscle. Insert the needle at a 45° angle to the skin.
- Separate two injections given in the same area of fatty tissue by a minimum of 1”.




Adapted by the Immunization Action Coalition, courtesy of the Minnesota Department of Health

www.immunize.org/catg.d/p2020A.pdf • Item #P2020A (7/06)



Patient name: \_\_\_\_\_ Date of birth: \_\_\_\_/\_\_\_\_/\_\_\_\_  
 (mo.) (day) (yr.)

# Screening Questionnaire for Adult Immunization



**For patients:** The following questions will help us determine which vaccines you may be given today. If you answer “yes” to any question, it does not necessarily mean you should not be vaccinated. It just means additional questions must be asked. If a question is not clear, please ask your healthcare provider to explain it.

	Yes	No	Don't Know
1. Are you sick today?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Do you have allergies to medications, food, or any vaccine?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Have you ever had a serious reaction after receiving a vaccination?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Do you have cancer, leukemia, AIDS, or any other immune system problem?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Do you take cortisone, prednisone, other steroids, or anticancer drugs, or have you had x-ray treatments?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Do you have a seizure, brain, or nerve problem?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. During the past year, have you received a transfusion of blood or blood products, or been given a medicine called immune (gamma) globulin?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. For women: Are you pregnant or is there a chance you could become pregnant during the next month?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Have you received any vaccinations in the past 4 weeks?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>


Form completed by: \_\_\_\_\_ Date: \_\_\_\_\_

Form reviewed by: \_\_\_\_\_ Date: \_\_\_\_\_

**Did you bring your immunization record card with you?**    **yes**     **no**

It is important for you to have a personal record of your vaccinations. If you don't have a record card, ask your healthcare provider to give you one! Bring this record with you every time you seek medical care. Make sure your healthcare provider records all your vaccinations on it.

## Information for Health Professionals about the Screening Questionnaire for Adults



Are you interested in knowing why we included a certain question on the Screening Questionnaire? If so, read the information below. If you want to find out even more, consult the references listed at the bottom of this page.

### 1. Are you sick today?

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events (1). However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (such as upper respiratory infections or diarrhea) are NOT contraindications to vaccination. Do not withhold vaccination if a person is taking antibiotics.

### 2. Do you have allergies to medications, food, or any vaccine?

History of anaphylactic reaction such as hives (urticaria), wheezing or difficulty breathing, or circulatory collapse or shock (not fainting) from a previous dose of vaccine or vaccine component is a contraindication for further doses. For example, if a person experiences anaphylaxis after eating eggs, do not administer influenza vaccine, or if a person has anaphylaxis after eating gelatin, do not administer MMR or varicella vaccine. Local reactions (e.g., a red eye following instillation of ophthalmic solution) are not contraindications. For an extensive list of vaccine components, see reference 2.

### 3. Have you ever had a serious reaction after receiving a vaccination?

History of anaphylactic reaction (see question 2) to a previous dose of vaccine or vaccine component is a contraindication for subsequent doses (1). Under normal circumstances, vaccines are deferred when a precaution is present. However, situations may arise when the benefit outweighs the risk (e.g., during a community measles outbreak).

### 4. Do you have cancer, leukemia, AIDS, or any other immune system problem?

Live virus vaccines (e.g., MMR, varicella, and the intranasal live attenuated influenza vaccine [LAIV]) are usually contraindicated in immunocompromised people. However, there are exceptions. For example, MMR vaccine is recommended for asymptomatic HIV-infected individuals who do not have evidence of severe immunosuppression. Immunosuppressed persons should not receive varicella vaccine or LAIV. For details, consult the ACIP recommendations (3, 4, 5).

### 5. Do you take cortisone, prednisone, other steroids, or anticancer drugs, or have you had x-ray treatments?

Live virus vaccines (e.g., MMR, varicella, LAIV) should be postponed until after chemotherapy or long-term high-dose steroid therapy has ended. For details and length of time to postpone, consult the ACIP statement (1, 5). To find specific vaccination schedules for stem cell transplant (bone marrow transplant) patients, see reference 6. LAIV can only be given to healthy non-pregnant individuals ages 5–49 years.

### 6. Do you have a seizure, brain, or nerve problem?

Tdap is contraindicated in persons who have a history of encephalopathy within 7 days following DTP/DTaP given before age 7 years. An unstable progressive neurologic problem is a precaution to the use of Tdap. For persons with stable neurologic disorders (including seizures) unrelated to vaccination, or for persons with a family history of seizure, vaccinate as usual. A history of Guillain-Barré syndrome (GBS) is a con-

sideration with the following: 1) Td/Tdap: if GBS has occurred within 6 weeks of a tetanus-containing vaccine and decision is made to continue vaccination, give Tdap instead of Td if no history of prior Tdap; 2) Inactivated influenza vaccine (TIV): if GBS has occurred within 6 weeks of prior TIV, vaccinate with TIV if at high risk for severe influenza complications; 3) LAIV: if GBS history, do not give LAIV; 4) MCV4: avoid vaccinating persons unless in recommended risk groups.

### 7. During the past year, have you received a transfusion of blood or blood products, or been given a medicine called immune (gamma) globulin?

Certain live virus vaccines (e.g., MMR, varicella) may need to be deferred, depending on several variables. Consult the most current ACIP recommendations for current information on intervals between immune globulin or blood product administration and MMR or varicella vaccination. (1)

### 8. For women: Are you pregnant or is there a chance you could become pregnant during the next month?

Live virus vaccines (e.g., MMR, varicella, LAIV) are contraindicated in the month before and during pregnancy because of the theoretical risk of virus transmission to the fetus. Sexually active women in their child-bearing years who receive MMR or varicella vaccination should be instructed to practice careful contraception for one month following receipt of either vaccine. On theoretical grounds, inactivated poliovirus vaccine should not be given during pregnancy; however, it may be given if risk of disease is imminent and immediate protection is needed (e.g., travel to endemic areas). Patients may be given Td routinely during 2nd or 3rd trimester if due for booster; if up to date and no history of Tdap, give 1 dose in immediate postpartum period, although some providers may choose to give Tdap during pregnancy. (1, 3, 4, 5, 7, 8)

### 9. Have you received any vaccinations in the past 4 weeks?

If the person to be vaccinated was given either live attenuated influenza vaccine (FluMist®) or an injectable live virus vaccine (e.g., MMR, varicella, yellow fever) in the past 4 weeks, they should wait 28 days before receiving another vaccination of this type. Inactivated vaccines may be given at any spacing interval if they are not administered simultaneously.

### References:

1. CDC. General recommendations on immunization. *MMWR* 2002; 51 (RR-2).
2. Table of Vaccine Components: [www.cdc.gov/nip/publications/pink/appendices/b/exipient-table-2.pdf](http://www.cdc.gov/nip/publications/pink/appendices/b/exipient-table-2.pdf).
3. CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. *MMWR* 1998; 47 (RR-8).
4. CDC. Prevention of varicella: updated recommendations of the ACIP. *MMWR* 1999; 48 (RR-6).
5. CDC. Prevention and control of influenza—recommendations of ACIP; at [www.cdc.gov/flu/professionals/vaccination](http://www.cdc.gov/flu/professionals/vaccination).
6. CDC. Excerpt from Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, *MMWR* 2000; 49 (RR-10), [www.cdc.gov/nip/publications/hstc-recs.pdf](http://www.cdc.gov/nip/publications/hstc-recs.pdf).
7. CDC. Notice to readers: Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. *MMWR* 2001; 50 (49).
8. CDC. Prevention of varicella. *MMWR* 1996; 45 (RR-11).



# Do I Need Any Vaccinations Today?

Many adults are behind on their vaccinations. This 2-page checklist will help your patients and you determine which vaccinations they need. CDC has reviewed the checklist for accuracy. It is copyright free. You can download full-size copies for your patients' use by going to [www.immunize.org/catg.d/4036need.pdf](http://www.immunize.org/catg.d/4036need.pdf).

For a ready-to-copy 8½ x 11" version of this 2-page piece, visit [www.immunize.org/catg.d/4036need.pdf](http://www.immunize.org/catg.d/4036need.pdf).

Your name: \_\_\_\_\_ Date of birth: \_\_\_\_/\_\_\_\_/\_\_\_\_ Today's date: \_\_\_\_/\_\_\_\_/\_\_\_\_  
 (mo) (day) (yr) (mo) (day) (yr)

### Do I Need Any Vaccinations Today?

Many adults are behind on their vaccinations. These checklists will help you and your healthcare provider determine if you need any vaccinations. Please check the boxes that apply to you.

#### Influenza vaccination

I am age 50 years or older.

I am younger than age 50 years, and one or more of the following conditions or situations applies to me:

- \_\_\_ I live in a nursing home or chronic care facility.
- \_\_\_ I will be pregnant during the influenza season (December–March).
- \_\_\_ I provide essential community services.
- \_\_\_ I am a healthcare worker.
- \_\_\_ I am a household contact or caregiver of a person who has one of the illnesses listed at the left, is age 65 years or older, or is age 0–59 months.

I am not in one of the groups listed above, but I'd like to be vaccinated to avoid getting influenza this season.

#### Pneumococcal vaccination

I am age 65 years or older, and I have never had a dose of pneumococcal vaccine.

I am age 65 years or older, and I have never had a dose of pneumococcal vaccine since that dose.

I have one of the following health problems and (  have ) (  have not ) had a previous dose of pneumococcal vaccine:

- \_\_\_ lung disease (not asthma) \_\_\_ liver disease \_\_\_ organ or bone marrow transplant
- \_\_\_ HIV/AIDS \_\_\_ generalized malignancy \_\_\_ diabetes \_\_\_ Hodgkin's disease \_\_\_ cerebrospinal fluid leak
- \_\_\_ alcoholism \_\_\_ leukemia \_\_\_ sickle cell disease
- \_\_\_ cochlear implant \_\_\_ multiple myeloma \_\_\_ had my spleen removed
- \_\_\_ kidney disease \_\_\_ lymphoma \_\_\_ on medication or receiving x-ray treatment that affects my immune system

#### Tetanus, diphtheria, and pertussis-containing vaccination (e.g., DTP, DTaP, Tdap, or Td)

I am younger than age 65 years and have not had a pertussis-containing vaccine as an adult.

I have or will have close contact with a child younger than 12 months and have not had a pertussis-containing vaccine as an adult.

I have not yet had at least 3 tetanus- and diphtheria-containing shots.

I have had at least 3 tetanus- and diphtheria-containing shots in my lifetime, but I believe it's been 10 years or more since I received my last shot.

I have no idea if I ever received any tetanus- and diphtheria-containing shots in school, the military, or elsewhere.

(continued on page 2)  
[www.immunize.org/catg.d/4036need.pdf](http://www.immunize.org/catg.d/4036need.pdf) • Item #4036 (7/06)  
 Immunization Action Coalition • 1573 Selby Ave. • St. Paul, MN 55104 • (651) 647-9009 • [www.vaccineinformation.org](http://www.vaccineinformation.org) • [www.immunize.org](http://www.immunize.org)

Page 2

#### Do I Need Any Vaccinations Today? (continued)

#### Hepatitis A vaccination

I am in one of the following risk groups, and I haven't had the 2-dose vaccination series against hepatitis A:

- I travel in countries other than the U.S., Western Europe, Canada, Japan, Australia, and New Zealand.<sup>1</sup>
- I use street drugs.
- I have chronic liver disease.
- I am a man who has sex with men.
- I have a clotting factor disorder.

I wish to receive hepatitis A vaccine to be protected against hepatitis A even though I am not in one of the above groups.

#### Hepatitis B vaccination

I am in one of the following risk groups, and I haven't completed the 3-dose vaccination series against hepatitis B:

- I live with a person who has long-term hepatitis B virus infection.
- I've been diagnosed with a sexually transmitted disease.
- I have had more than one sex partner in a 6-mo. period.
- I am a man who has sex with men.
- I am a healthcare or public safety worker who is exposed to blood or body fluids.
- I am an immigrant, or my parents are immigrants from an area of the world where hepatitis B is common.<sup>2,3</sup>
- I inject street drugs.
- I am a sex partner of a person with hepatitis B.
- I travel outside the U.S.<sup>3</sup>

I wish to receive hepatitis B vaccine to be protected against hepatitis B even though I am not in one of the above groups.

#### Measles-Mumps-Rubella (MMR) vaccination

I was born after 1956 and never received a dose of MMR.

I am a woman thinking about a future pregnancy and do not know if I'm immune to rubella.

I am included in one of the following groups for whom 2 doses of MMR are recommended, but I have received only 1 dose of MMR.

- \_\_\_ I am a healthcare worker. \_\_\_ I am entering college or a post-high-school educational institution.
- \_\_\_ I travel internationally. \_\_\_ I had a blood test that shows I do not have immunity to measles, mumps, or rubella.

#### Chickenpox (varicella) vaccination

I have never had chickenpox disease or varicella vaccination.

I'm not sure if I've had chickenpox or not.

I may become pregnant and do not know if I'm immune to chickenpox.

#### Meningococcal vaccination

I am (or will be) a college freshman living in a dorm.

I am traveling to an area of the world where meningococcal disease is common.<sup>1</sup>

I have sickle cell disease, or my spleen isn't working or has been removed.

#### Human papillomavirus vaccination

I am a woman younger than age 27 years and haven't completed a 3-dose vaccination series against human papillomavirus.

#### Shingles (zoster) vaccination

I am an adult age 60 years or older and haven't been vaccinated against shingles.

**Note:** Adults may need additional vaccines, such as Hib, polio, or others. Talk to your healthcare provider.

1. Call your local travel clinic to find out if additional vaccines are recommended.

2. Areas with high rates of hepatitis B include Africa, China, Korea, Southeast Asia (including Indonesia and the Philippines, the Middle East except Israel, South and Western Pacific islands, northern Amazon Basin, and certain parts of the Caribbean (i.e., Haiti and the Dominican Republic)). Areas with moderate rates include South Central and Southwest Asia, Israel, Japan, Eastern and Southern Europe, Russia, and most of Central and South America.

3. Adults from these areas should be tested for hepatitis B when they receive the first dose of hepatitis B vaccine (during the same visit).



